{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T02:59:58Z","timestamp":1781146798892,"version":"3.54.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Assessing the stage of maturation is critical for the classification of T-cell neoplasms and is helpful in minimal\/measurable residual disease (MRD) testing for T-lymphoblastic leukemia (T-ALL). This study analyzes the utility of CD48 in characterizing T-cell neoplasms at diagnosis and posttherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective review characterizes the expression of CD48 in T-ALL and mature T-cell neoplasms at diagnosis and posttreatment. CD48 intensity was assessed qualitatively by flow cytometry relative to the background T cells. Potential confounders were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>T cells show increases in CD48 expression with progressive maturation, with high-level expression on mature T cells. CD48 expression by flow cytometry was decreased to absent (compared with expression on mature T cells) in 100% of T-ALL cases at diagnosis and in 92% of cases positive for MRD posttherapy. By contrast, among mature T-cell neoplasms, CD48 expression at diagnosis overlapped with expression on background mature T cells in most cases (91%). Reduced CD48 expression on background, nonneoplastic T cells was seen in the setting of alemtuzumab therapy and in samples with glycosylphosphatidylinositol (GPI)\u2013deficient populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CD48 expression is diminished compared with normal background T cells in most cases of T-ALL at diagnosis and posttherapy, whereas it was typically retained in mature T-cell\/natural killer\u2013cell neoplasms. While CD48 levels may fluctuate after chemotherapy in T-ALL, reduced CD48 can be used as a marker of immaturity in most MRD cases. Potential confounders in the assessment of CD48 include alemtuzumab therapy and the presence of GPI-deficient populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqag060","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:19:04Z","timestamp":1777637944000},"source":"Crossref","is-referenced-by-count":0,"title":["CD48 expression in T-lymphoblastic leukemia\/lymphoma and mature T-cell neoplasms: role in detecting measurable residual disease and potential confounders, a single-institution retrospective review"],"prefix":"10.1093","volume":"165","author":[{"given":"Alireza","family":"Torabi","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R","family":"Fromm","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Dorer","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA,","place":["United States"]},{"name":"Department of Pathology, University of Alabama , Birmingham, AL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Glynn","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin L","family":"Edlefsen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Shameli","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu","family":"Cherian","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2026061022551041200_aqag060-B1","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1080\/10428194.2018.1522442","article-title":"Incidence and survival of T-cell acute lymphoblastic leukemia in the United States","volume":"60","author":"Guru Murthy","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2026061022551041200_aqag060-B2","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1182\/blood.v99.12.4386","article-title":"Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL","volume":"99","author":"Willemse","year":"2002","journal-title":"Blood"},{"key":"2026061022551041200_aqag060-B3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","article-title":"Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial","volume":"15","author":"Vora","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026061022551041200_aqag060-B4","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1182\/blood.2023020678","article-title":"Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children\u2019s Oncology Group study","volume":"142","author":"Wood","year":"2023","journal-title":"Blood"},{"key":"2026061022551041200_aqag060-B5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/bjh.12042","article-title":"The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children\u2019s Oncology Group report","volume":"159","author":"Patel","year":"2012","journal-title":"Br J Haematol"},{"key":"2026061022551041200_aqag060-B6","first-page":"277","article-title":"013 (CD99) positivity in hematologic proliferations correlates with TdT positivity","volume":"10","author":"Robertson","year":"1997","journal-title":"Mod Pathol"},{"key":"2026061022551041200_aqag060-B7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/cyto.b.20511","article-title":"Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection","volume":"78","author":"Roshal","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"2026061022551041200_aqag060-B8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/cyto.b.20087","article-title":"Normal patterns of expression of glycosylphosphatidylinositol-anchored proteins on different subsets of peripheral blood cells: a frame of reference for the diagnosis of paroxysmal nocturnal hemoglobinuria","volume":"70","author":"Hernandez-Campo","year":"2006","journal-title":"Cytometry B Clin Cytom"},{"key":"2026061022551041200_aqag060-B9","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1084\/jem.181.4.1445","article-title":"Early human T cell development: analysis of the human thymus at the time of initial entry of hematopoietic stem cells into the fetal thymic microenvironment","volume":"181","author":"Haynes","year":"1995","journal-title":"J Exp Med"},{"key":"2026061022551041200_aqag060-B10","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1182\/blood.V118.21.2547.2547","article-title":"High-throughput screening by flow cytometry identifies reduced expression of CD48 as a universal characteristic of T-ALL and a suitable target for minimal residual disease (MRD) detection","volume":"118","author":"Wood","year":"2011","journal-title":"Blood"},{"key":"2026061022551041200_aqag060-B11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/ejh.70035","article-title":"CD48 is a robust marker and a useful addition for assessment of measurable residual disease in T-cell acute lymphoblastic leukemia","volume":"115","author":"Srinivasan","year":"2025","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"2026061022551041200_aqag060-B12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ijlh.13011","article-title":"Sensitive and accurate identification of PNH clones based on ICCS\/ESCCA PNH Consensus Guidelines\u2014a summary","volume":"41","author":"Illingworth","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"2026061022551041200_aqag060-B13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/cyto.b.21845","article-title":"Flow cytometric features of incidental indolent T lymphoblastic proliferations","volume":"98","author":"Fromm","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"key":"2026061022551041200_aqag060-B14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/cyto.b.21833","article-title":"Applications of flow cytometric immunophenotyping in the diagnosis and posttreatment monitoring of B and T lymphoblastic leukemia\/lymphoma","volume":"96","author":"DiGiuseppe","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"key":"2026061022551041200_aqag060-B15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/cyto.b.21939","article-title":"Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion","volume":"100","author":"Tembhare","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"key":"2026061022551041200_aqag060-B16","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41375-018-0039-7","article-title":"Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group (COG)","volume":"32","author":"Gupta","year":"2018","journal-title":"Leukemia"},{"key":"2026061022551041200_aqag060-B17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/cyto.b.20071","article-title":"Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children\u2019s oncology group","volume":"68","author":"Borowitz","year":"2005","journal-title":"Cytometry B Clin Cytom"},{"key":"2026061022551041200_aqag060-B18","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1084\/jem.169.3.1087","article-title":"Blast-1 possesses a glycosyl-phosphatidylinositol (GPI) membrane anchor, is related to LFA-3 and OX-45, and maps to chromosome 1q21-23","volume":"169","author":"Staunton","year":"1989","journal-title":"J Exp Med"},{"key":"2026061022551041200_aqag060-B19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/cyto.b.22242","article-title":"A 20-color 21-antigen flow cytometric assay for disease monitoring of T-cell lymphoblastic leukemia","volume":"108","author":"Gao","year":"2025","journal-title":"Cytometry B Clin Cytom"},{"key":"2026061022551041200_aqag060-B20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/cyto.a.24805","article-title":"FCM marker importance for MRD assessment in T-cell acute lymphoblastic leukemia: an AIEOP-BFM-ALL-FLOW study group report","volume":"105","author":"Kowarsch","year":"2024","journal-title":"Cytometry A"},{"key":"2026061022551041200_aqag060-B21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1309\/AJCPG71KYOXTKLQW","article-title":"Immunophenotypic characterization of T-cell prolymphocytic leukemia","volume":"140","author":"Chen","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"2026061022551041200_aqag060-B22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/10428190500052156","article-title":"CD52 expression in T-cell large granular lymphocyte leukemia\u2014implications for treatment with alemtuzumab","volume":"46","author":"Osuji","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"2026061022551041200_aqag060-B23","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/S2352-3026(15)00227-6","article-title":"Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study","volume":"3","author":"Dumitriu","year":"2016","journal-title":"Lancet Haematol"},{"key":"2026061022551041200_aqag060-B24","doi-asserted-by":"publisher","first-page":"e39416","DOI":"10.1371\/journal.pone.0039416","article-title":"Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis","volume":"7","author":"Rao","year":"2012","journal-title":"PLoS One"},{"key":"2026061022551041200_aqag060-B25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/sj.bmt.1705049","article-title":"Early emergence of PNH-like T cells after allogeneic stem cell transplants utilising CAMPATH-1H for T cell depletion","volume":"36","author":"Garland","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2026061022551041200_aqag060-B26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00277-010-1026-x","article-title":"T-cell prolymphocytic leukaemia: spontaneous immunophenotypical switch from CD4 to CD8 expression","volume":"90","author":"Tse","year":"2011","journal-title":"Ann Hematol"},{"key":"2026061022551041200_aqag060-B27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clim.2016.01.008","article-title":"Roles of CD48 in regulating immunity and tolerance","volume":"164","author":"McArdel","year":"2016","journal-title":"Clin Immunol"},{"key":"2026061022551041200_aqag060-B28","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1182\/blood.V126.23.2223.2223","article-title":"Insights into clonal relationships of putative adaptive natural killer cells (NK) in humans, via mapping of somatic piga mutations in patients with paroxysmal nocturna hemoglobinuria (PNH)","volume":"126","author":"Winkler","year":"2015","journal-title":"Blood"},{"key":"2026061022551041200_aqag060-B29","doi-asserted-by":"publisher","first-page":"e0078923","DOI":"10.1128\/mbio.00789-23","article-title":"Impact of HIV-1 Vpu-mediated downregulation of CD48 on NK-cell-mediated antibody-dependent cellular cytotoxicity","volume":"14","author":"Marchitto","year":"2023","journal-title":"mBio"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/6\/aqag060\/68505508\/aqag060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/6\/aqag060\/68505508\/aqag060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T02:55:23Z","timestamp":1781146523000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqag060\/8705218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqag060","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"aqag060"}}